What is CJC-1295?
CJC-1295 is an analogue of growth-hormone-releasing hormone designed for prolonged stimulation of the growth-hormone axis.
Proposed mechanism
It acts through the GHRH receptor pathway, stimulating pituitary growth-hormone release and downstream IGF-1 production.
What has been published?
A 2006 publication reported randomized placebo-controlled ascending-dose trials in healthy adults with sustained increases in GH and IGF-1.
Current human evidence
Human pharmacology demonstrates biological activity, but evidence for many performance, recovery and anti-ageing claims remains inadequate.
Regulatory status
CJC-1295 is not an FDA-approved drug. FDA notes limited clinical data and safety concerns in the compounding context.
Possible areas of research interest
- Growth-hormone physiology
- IGF-1 signalling
- Long-acting peptide design
- Endocrine pharmacology
Important limitations
- Clinical studies are small and early-stage
- Long-term benefit-risk profile is not established
- Popular performance claims are not proven indications
- Research products may introduce identity and purity uncertainty
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.